Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

ABIONYX Pharma SA (0RAG) Share Price & Analysis

0 Followers

0RAG Stock Chart & Stats

€1.61€0.07(6.89%)
At close: 4:30 PM GMT
€1.5€1.75€2Aug 17Aug 31Sep 14Sep 28Oct 13Oct 26Nov 9
Day’s Range
EUR 1.61 - EUR 1.61
52-Week Range
EUR 1.45 - EUR 4.47
Previous Close
EUR 1.51
Volume
N/A
Average Volume (3M)
165
Market Cap
EUR 71.98M
Enterprise Value
EUR 62.06M
Total Cash (Recent Filing)
EUR 26.87M
Total Debt (Recent Filing)
EUR 15.18M
Price to Earnings (P/E)
―
Beta
0.23
Next Earnings
Mar 16, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Specialized HDL Biology Platform

The company has a clearly defined therapeutic platform centered on apoA-I and HDL biology, giving its research effort a coherent scientific focus. A specialized platform can support development across multiple severe inflammatory and infectious indications if clinical work continues to validate the approach.

Lead Program Addresses Severe Conditions

A lead program aimed at severe inflammatory and infectious conditions targets areas where meaningful therapeutic need may support clinical and commercial relevance. Concentrating resources around a defined lead candidate also provides a clearer basis for future development milestones.

Positive Remaining Equity Base

Despite substantial deterioration, the company retains a positive equity base, which is stronger than an already negative net-asset position. This provides some remaining balance-sheet support for ongoing research and may preserve limited flexibility while management works to advance its pipeline.

Bears Say

Large Operating Losses And Weak Margins

Very large operating losses relative to revenue show that the current business has not reached economic scale. The sharp gross-margin deterioration further weakens the prospect of near-term self-funded growth, making improved economics dependent on stronger revenue or substantial cost restructuring.

Persistent Cash Burn

Ongoing operating and free-cash-flow outflows indicate that research and corporate activities continue to consume cash rather than generate it. Without a step-change in revenue or costs, this burn profile implies continuing financing requirements and reduces the company’s ability to fund development internally.

Rising Leverage And Eroding Equity

Higher leverage alongside a shrinking equity base reduces financial flexibility and increases the sensitivity of the company to further losses. This balance-sheet trend can constrain investment in the pipeline and make future funding more important as development spending continues.

ABIONYX Pharma SA News

0RAG FAQ

What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest share price was €1.45 and its highest was €4.47 in the past 12 months.
What is ABIONYX Pharma SA’s market cap?
ABIONYX Pharma SA’s market cap is €71.98M.
When is ABIONYX Pharma SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ABIONYX Pharma SA’s earnings last quarter?
ABIONYX Pharma SA released its earnings results on Sep 23, 2026. The company reported -€0.134 earnings per share for the quarter.
Is ABIONYX Pharma SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does ABIONYX Pharma SA pay dividends?
ABIONYX Pharma SA does not currently pay dividends.
What is ABIONYX Pharma SA’s EPS estimate?
ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABIONYX Pharma SA have?
ABIONYX Pharma SA has 44,067,715 shares outstanding.
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
ABIONYX Pharma SA reported an EPS of -€0.134 in its last earnings report. Following the earnings report the stock price went up 3.541%.
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
Currently, no hedge funds are holding shares in GB:0RAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology